Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2022

Open Access 01-12-2022 | Irritable Bowel Syndrome | Opinion

Immune responses in the irritable bowel syndromes: time to consider the small intestine

Authors: Grace L. Burns, Nicholas J. Talley, Simon Keely

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

Irritable bowel syndrome (IBS) is considered a disorder of gut-brain interaction (DGBI), presenting as chronic abdominal pain and altered defaecation. Symptoms are often food related. Much work in the field has focused on identifying physiological, immune and microbial abnormalities in the colon of patients; however, evidence of small intestinal immune activation and microbial imbalance has been reported in small studies. The significance of such findings has been largely underappreciated despite a growing body of work implicating small intestinal homeostatic imbalance in the pathogenesis of DGBIs.

Main text

Small intestinal mechanosensation is a characteristic feature of IBS. Furthermore, altered small intestinal barrier functions have been demonstrated in IBS patients with the diarrhoea-predominant subtype. Small intestinal bacterial overgrowth and increased populations of small intestinal mast cells are frequently associated with IBS, implicating microbial imbalance and low-grade inflammation in the pathogenesis of IBS. Furthermore, reports of localised food hypersensitivity responses in IBS patients implicate the small intestine as the site of immune-microbial-food interactions.

Conclusions

Given the association of IBS symptoms with food intake in a large proportion of patients and the emerging evidence of immune activation in these patients, the current literature suggests the pathogenesis of IBS is not limited to the colon but rather may involve dysfunction of the entire intestinal tract. It remains unclear if regional variation in IBS pathology explains the various symptom phenotypes and further work should consider the intestinal tract as a whole to answer this question.
Literature
1.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.e2.CrossRef
2.
Kibune Nagasako C, et al. Irritable bowel syndrome subtypes: clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108(2):59–64.PubMed
3.
Burns G, et al. Immune activation in functional gastrointestinal disorders. Gastroenterol Hepatol (NY). 2019;15(10):539–48.
4.
Burns G, et al. Evidence for local and systemic immune activation in functional dyspepsia and the irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2019;114(3):429–36.PubMedCrossRef
5.
Worbs T, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med. 2006;203(3):519–27.PubMedPubMedCentralCrossRef
6.
7.
Fritscher-Ravens A, et al. Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Gastroenterology. 2019;157(1):109–118 e5.PubMedCrossRef
8.
Turcotte J-F, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc. 2013;77(4):624–30.PubMedCrossRef
9.
Grover M, et al. Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. Aliment Pharmacol Ther. 2021;54(9):1179–92.PubMedCrossRef
10.
Wang XJ, et al. Differential mRNA expression in ileal mucosal biopsies of patients with diarrhea- or constipation-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2021;12(4):e00329.PubMedPubMedCentralCrossRef
11.
Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667–85.PubMedCrossRef
12.
Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999;46(3):183–96.PubMed
13.
Proano M, et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol. 1990;258(6 Pt 1):G856–62.PubMed
14.
Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14(1):20–32.PubMedCrossRef
15.
Agace WW, McCoy KD. Regionalized development and maintenance of the intestinal adaptive immune landscape. Immunity. 2017;46(4):532–48.PubMedCrossRef
16.
17.
Yantiss RK. Eosinophils in the GI tract: how many is too many and what do they mean? Mod Pathol. 2015;28(S1):S7–S21.PubMedCrossRef
18.
Straumann A, Simon HU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy. 2004;59(1):15–25.PubMedCrossRef
19.
Dubois A, et al. Regulation of Th2 responses and allergic inflammation through bystander activation of CD8+ T lymphocytes in early life. J Immunol. 2010;185(2):884–91.PubMedCrossRef
20.
Parrish A, et al. Intestinal mucus barrier: a missing piece of the puzzle in food allergy. Trends Mol Med. 2022;28(1):36–50.PubMedCrossRef
21.
22.
23.
24.
Bashashati M, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26(7):1036–48.PubMedCrossRef
25.
Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771–7.PubMedCrossRef
26.
Rodríguez-Fandiño OA, et al. Maturation phenotype of peripheral blood monocyte/macrophage after stimulation with lipopolysaccharides in irritable bowel syndrome. J Neurogastroenterol Motil. 2017;23(2):281–8.PubMedPubMedCentralCrossRef
27.
Nasser Y, et al. Activation of peripheral blood CD4+ T-cells in IBS is not associated with gastrointestinal or psychological symptoms. Sci Rep. 2019;9(1):3710.PubMedPubMedCentralCrossRef
28.
Ohman L, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(5):1205–12.PubMedCrossRef
29.
Belmonte L, et al. Role of Toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One. 2012;7(8):e42777.PubMedPubMedCentralCrossRef
30.
Brint EK, et al. Differential expression of Toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106(2):329–36.PubMedCrossRef
31.
Langhorst J, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(2):404–10.PubMedCrossRef
32.
McKernan DP, et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther. 2011;33(9):1045–52.PubMedCrossRef
33.
Bashashati M, et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(1):e13192.
34.
Vicario M, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut. 2015;64(9):1379–88.PubMedCrossRef
35.
Walker MM, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29(7):765–73.PubMedPubMedCentralCrossRef
36.
Guilarte M, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203–9.PubMedCrossRef
37.
Barbara G, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.PubMedCrossRef
38.
O’Sullivan M, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12(5):449–57.PubMedCrossRef
39.
Weston AP, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38(9):1590–5.PubMedCrossRef
40.
Robles A, et al. Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2019;31(12):e13718.PubMedCrossRef
41.
42.
Barbara G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37.PubMedCrossRef
43.
Vivinus-Nébot M, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol. 2012;107(1):75–81.PubMedCrossRef
44.
Piche T, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57(4):468–73.PubMedCrossRef
45.
Park JH, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(1 Pt 1):71–8.PubMedCrossRef
46.
Casado-Bedmar M, et al. Elevated F-EDN correlates with mucosal eosinophil degranulation in patients with IBS—a possible association with microbiota? J Leukoc Biol. 2021.1-11.
47.
De Silva AP, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol. 2012;47(6):619–24.PubMedCrossRef
48.
Singh M, et al. The relationship between mucosal inflammatory cells, specific symptoms, and psychological functioning in youth with irritable bowel syndrome. Sci Rep. 2020;10(1):11988.PubMedPubMedCentralCrossRef
49.
Katinios G, et al. Increased colonic epithelial permeability and mucosal eosinophilia in ulcerative colitis in remission compared with irritable bowel syndrome and health. Inflamm Bowel Dis. 2020;26(7):974–84.PubMedPubMedCentralCrossRef
50.
Willot S, et al. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(8):734–e347.PubMedCrossRef
51.
52.
53.
Kindt S, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21(4):389–98.PubMedCrossRef
54.
Liebregts T, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913–20.PubMedCrossRef
55.
56.
Newcomb DC, Peebles RS Jr. Th17-mediated inflammation in asthma. Curr Opin Immunol. 2013;25(6):755–60.PubMedCrossRef
57.
Choghakhori R, et al. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: association with digestive symptoms and quality of life. Cytokine. 2017;93:34–43.PubMedCrossRef
58.
Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809.PubMedCrossRef
59.
60.
Martínez C, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62(8):1160–8.PubMedCrossRef
61.
62.
Mujagic Z, et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther. 2014;40(3):288–97.PubMedCrossRef
63.
Salvo-Romero E, et al. Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in diarrhea-predominant irritable bowel syndrome. Sci Rep. 2020;10(1):20706.PubMedPubMedCentralCrossRef
64.
Guilarte M, et al. Peripheral corticotropin-releasing factor triggers jejunal mast cell activation and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2020;115(12):2047–59.PubMedCrossRef
65.
Bruce JK, et al. Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia. Brain Behav Immun. 2022;101:335–45.PubMedCrossRef
66.
Foley S, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology. 2011;140(5):1434–43 e1.PubMedCrossRef
67.
Törnblom H, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123(6):1972–9.PubMedCrossRef
68.
Park JH, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18(7):539–46.PubMedCrossRef
69.
Talley NJ, et al. Ileocolonic histopathological and microbial alterations in the irritable bowel syndrome: a nested community case-control study. Clin Transl Gastroenterol. 2020;12(1):e00296.PubMedPubMedCentralCrossRef
70.
Najjar SA, et al. Optogenetic activation of the distal colon epithelium engages enteric nervous system circuits to initiate motility patterns. Am J Physiol-Gastrointest Liver Physiol. 2021;321(4):G426-435.PubMedCrossRef
71.
Böhn L, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Off J Am Coll Gastroenterol. 2013;108(5):634–41.CrossRef
72.
73.
Pittayanon R, et al. Gut microbiota in patients with irritable bowel syndrome—a systematic review. Gastroenterology. 2019;157(1):97–108.PubMedCrossRef
74.
Hugerth LW, et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076–84.PubMedCrossRef
75.
Jeffery IB, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997–1006.PubMedCrossRef
76.
Jalanka-Tuovinen J, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63(11):1737–45.PubMedCrossRef
77.
El-Salhy M, Hausken T, Hatlebakk JG. Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterol Motil. 2021;33(11):e14157.
78.
Liu Y, et al. Increased ileal immunoglobulin A production and immunoglobulin A-coated bacteria in diarrhea-predominant irritable bowel syndrome. Clinical and Translational. Gastroenterology. 2020;11(3):e00146.
79.
Paik CN, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.PubMedCrossRef
80.
Pimentel M, et al. ACG Clinical Guideline: small intestinal bacterial overgrowth. Off J Am Coll Gastroenterol. 2020;115(2):165–78.CrossRef
81.
Moraru IG, et al. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. Rom J Intern Med. 2014;52(3):143–50.PubMed
82.
Ghoshal UC, et al. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. J Gastroenterol Hepatol. 2020;35(6):922–31.PubMedCrossRef
83.
Shah A, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190–201.PubMedCrossRef
84.
Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut and Liver. 2017;11(2):196–208.PubMedPubMedCentralCrossRef
85.
Yao CK, Tuck CJ. The clinical value of breath hydrogen testing. J Gastroenterol Hepatol. 2017;32:20–2.PubMedCrossRef
86.
Shah A, Morrison M, Holtmann GJ. Gastroduodenal “dysbiosis”: a new clinical entity. Curr Treat Opt Gastroenterol. 2018;16(4):591–604.CrossRef
87.
88.
Rezaie A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–84.PubMedPubMedCentralCrossRef
89.
Sundin OH, et al. Does a glucose-based hydrogen and methane breath test detect bacterial overgrowth in the jejunum? Neurogastroenterol Motil. 2018;30(11):e13350.PubMedCrossRef
90.
Srivastava D, et al. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26(10):1408–16.PubMedCrossRef
91.
Rivkin A, Rybalov S. Update on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadoline. Pharmacother: J Hum Pharmacol Drug Ther. 2016;36(3):300–16.CrossRef
92.
Xu D, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484–496.e4.PubMedCrossRef
93.
Wauters L, et al. Duodenal inflammation: an emerging target for functional dyspepsia? Expert Opin Ther Targets. 2020;24(6):511–23.PubMedCrossRef
94.
95.
von Wulffen M, et al. Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: prevalence and risk factors. Dig Dis Sci. 2019;64(2):480–6.CrossRef
96.
Spiller R. Postinfectious functional dyspepsia and postinfectious irritable bowel syndrome: different symptoms but similar risk factors. Gastroenterology. 2010;138(5):1660–3.PubMedCrossRef
97.
Talley NJ. What causes functional gastrointestinal disorders? A proposed disease model. Am J Gastroenterol. 2020;115(1):41–8.PubMedCrossRef
Metadata
Title
Immune responses in the irritable bowel syndromes: time to consider the small intestine
Authors
Grace L. Burns
Nicholas J. Talley
Simon Keely
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02301-8

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue

Research article

A positive faecal immunochemical test result and its association with the incidence of rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis: an analysis of one-million national colorectal cancer screening programme results

Research article

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Research article

Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic

Correspondence

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Research article

Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease

Research article

The UK Coronavirus Job Retention Scheme and diet, physical activity, and sleep during the COVID-19 pandemic: evidence from eight longitudinal population surveys